High-flow port and infusion needle systems

Information

  • Patent Grant
  • 10166321
  • Patent Number
    10,166,321
  • Date Filed
    Friday, January 9, 2015
    9 years ago
  • Date Issued
    Tuesday, January 1, 2019
    5 years ago
Abstract
The present invention relates to a multi-reservoir port, catheter and non-coring needle systems that support high-flow applications such as hemodialysis and apheresis. In particular, the present invention relates to improvements to each of these systems to provide optimal flow rates and septum life with minimal intraluminal pressure; both individually and in combination.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. provisional application No. 61/925,287 filed on Jan. 9, 2014, of which is incorporated herein by reference in its entireties.


FIELD OF THE INVENTION

The present invention relates generally to the field of vascular access ports. More specifically, the present invention relates to multi-reservoir port and infusion needle systems that support high-flow applications such as hemodialysis and apheresis.


BACKGROUND OF THE INVENTION

Multi-lumen catheters are commonly used for extracorporeal procedures in which blood is removed from the vascular system through an aspiration lumen, treated and returned to circulation through an infusion lumen. Apheresis is one example an extracorporeal procedure in which a patient's blood is removed from the vascular system, passed through a machine that removes specific blood components (e.g., plasma, red blood cells, white blood cells and/or platelets etc.) and then returned to circulation. Apheresis procedures generally last from one to four hours, although these times may vary depending on the procedure being performed, the medical condition being treated, the size of the patient and the type of machine being used. The number of treatments also varies based on the procedure being performed. Some procedures, such as red blood cell exchange, are only performed once. In other situations the patient is re-evaluated after two or three procedures to determine if they are responding to the treatment. Certain diseases require a pre-set treatment schedule that may include, for example, five procedures over the course of two weeks. Other procedures require the patient to follow a routine schedule of treatment that may vary from multiple times per week to once per month. Examples of apheresis procedures that require frequent treatments include plasma exchange (e.g., the removal of harmful substances from the blood plasma and subsequent replacement with saline, normal serum albumin or fresh frozen plasma); low density lipoprotein (LDL) apheresis (e.g., to treat familial hypercholesterolemia); photopheresis (e.g., to treat graft-versus-host disease; cutaneous T-cell lymphoma; or heart transplant rejection); allo- and autoantibody removal (e.g., to treat autoimmune disease; hemophilia; or transplant rejection); leukocytapheresis (e.g., to remove malignant white blood cells in leukemia) and thrombocytapheresis (e.g., to treat essential thrombocythemia; or polycythemia vera). Hemodialysis is another example of an extracorporeal procedure in which waste products, such as creatinine, urea, potassium, phosphate and/or free water, are removed from the blood of a patient whose kidneys are in a state of renal failure. In general, hemodialysis treatments are required once a patient has lost 85 to 90 percent of their kidney function. A typical treatment schedule requires performing hemodialysis 3 times a week, although patients who have retained substantial residual kidney function might only require sessions twice-a-week. Larger patients, or patients who have difficulties with fluid overload, may require four hemodialysis sessions per week are often prescribed for larger patients. Short daily home hemodialysis treatments may be performed as frequently as five to seven times per week. While both procedures require the continued re-circulation of blood through an external apparatus, the flow rates required for hemodialysis generally exceed those required for apheresis. For example, hemodialysis typically requires flow rates in the range 300-400 ml/min, but can sometimes exceed 800 ml/min. By contrast, the flow rates required for apheresis procedures can range from 30-60 ml/min (e.g., red blood cell exchange) to 150 ml/min (e.g., plasma exchange).


Medical professionals often prefer the use of implantable ports over peripherally inserted central catheters (i.e., PICCs) for procedures such as apheresis and hemodialysis that require repeated and/or prolonged access to the vascular system. One advantage of implantable ports is that they are completely indwelling, and therefore minimize the risk of infection, especially in patients requiring chronic care. Implantable ports are also more amenable to patients with active lifestyles since their relatively low profile allows them to be easily hidden from view. Ports are typically implanted in the patient's chest and connected to a catheter having a distal tip positioned at the point of treatment. For example, for many medical procedures the catheter tip is positioned at the junction of the superior vena cava and the right atrium. Implantable ports generally include a reservoir (i.e., chamber) in fluid communication with a catheter. The reservoir is typically covered by a needle-penetrable and self-sealing elastomeric septum. The self-sealing septum allows the reservoir to be accessed by puncturing both the patient's skin and the septum with a needle, for example, to infuse and/or aspirate fluid to and from the distal tip of the catheter.


For medical procedures that require multi-lumen access to the vascular system it is common for two ports to be implanted within the patient. While a variety of arrangements are possible, it is most common for one port to be implanted within the patient's left arm and the other port implanted within the right arm. In addition to the increased cost associated with implanting two ports, the separate invasive procedures dramatically increases patient discomfort and the likelihood of negative outcomes such as infection. These problems may be avoided by implanting a multi-reservoir port, which allows the administration of fluid through one reservoir and aspiration of fluid through a separate reservoir. While multi-reservoir ports are more cost-efficient, minimize patient discomfort and decrease patient exposure, they do have drawbacks.


Since fluid flows through a conventional multi-reservoir port (including the catheter) as a continuous stream, it is important that pressure on the aspiration side remains equal (i.e., balanced) to the pressure on the infusion side. With the power source for fluid flow provided by the apheresis or hemodialysis machine, fluid is essentially pulled through the aspiration side under negative pressure and pushed through the infusion side under positive pressure. This requires fluid on the aspiration side to travel a greater distance to reach the power source than fluid on the infusion side, resulting in the formation of high intraluminal negative pressures. These negative pressures force the lumen of the aspiration catheter to collapse or constrict, thereby restricting the flow of fluid throughout the entire system. To avoid harming the patient, automated apheresis and hemodialysis machines are designed to set-off pressure alarms when high intraluminal pressure is detected.


To maintain the proper pressure balance within multi-reservoir port systems, medical professionals typically access the aspiration reservoir of conventional multi-reservoir port systems with a 16 gauge needle. The large inner diameter of the 16 gauge needle is preferred over smaller 18 or 19 gauge needles because they allow fluid to flow into the aspiration reservoir under minimal pressure such that pressure alarms are not set-off. Due to its large inner diameter, a trocar is inserted into the lumen of the 16 gauge needle to prevent coring of the elastomeric septum covering the aspiration reservoir. Unfortunately, the size and shape of standard 16 gauge trocar needles creates large puncture sites within the elastomeric septum. Repeated overlapping punctures by the 16 gauge trocar eventually result in the formation of leakage sites within the septum, ultimately rendering the port unsuitable for safe and reliable use.


As evidenced by the competing interests of maintaining septum integrity and avoiding high intraluminal negative pressure, there is a continuing need for multi-reservoir port and non-coring needle systems that support high-flow applications with minimal impact on the puncture life of the elastomeric septum.


SUMMARY OF THE INVENTION

The present invention relates generally to multi-reservoir port, catheter and non-coring needle systems that support high-flow applications such as hemodialysis and apheresis. In one aspect, the present invention relates to improved port, catheter and needle systems that provide, both alone and in combination, optimal flow rates and septum puncture life with minimal intraluminal pressure.


In one embodiment, the present invention relates to a high flow multi-reservoir port assembly, comprising a vascular access port that includes a housing defining first (i.e., aspiration) and second (i.e., infusion) reservoirs. A first septum is mounted within the housing to seal the first reservoir, and a second septum is mounted within the housing to seal the second reservoir. The first and second septa (plural) are configured to be penetrable by a needle, and self-sealing after the needle is withdrawn. An inlet stem with an inlet lumen is in fluid communication with the first reservoir, and an outlet stem with an outlet lumen is in fluid communication with the second reservoir. The inlet and outlet stems are in fluid communication with a dual-lumen catheter that includes a proximal end, a distal end and first and second lumens extending therebetween. The catheter includes a smooth outer surface having a substantially circular outer diameter. The inlet stem is dimensioned to receive the first lumen at the proximal end of the catheter, and the outlet stem is dimensioned to receive the second lumen at the proximal end of the catheter. The first and second septa comprise an elastomeric material, including, for example, a multi-durometer material. The elastomeric material is self-sealing. The multi-durometer elastomeric material may comprise a first layer with a first durometer and a second layer with a second durometer. For example, the durometer of the material of the first layer may be less than the durometer of the material of the second layer. The first layer may be disposed above (i.e., on top of) the second layer. Alternatively, the first layer may surround the second layer. The first layer may also be disposed both above and below the second layer, such that the second layer is effectively sandwiched between two first layers. The first and second layers may include a variety of thicknesses. For example, the thickness of the second layer may be greater than the thickness of the first layer. Alternatively, the thickness of the first and second layers may be substantially the same. The first lumen of the catheter comprises a first inner diameter, and the second lumen of the catheter comprises a second inner diameter, wherein the second inner diameter is smaller than the first inner diameter. The first and second lumens of the catheter may include a variety of shapes. For example, the first inner diameter may define a substantially oval shape, while the second inner diameter may define a substantially concave shape. The first and second lumens of the catheter also define respective first and second openings at the distal end of the catheter. The openings do not necessarily terminate at the same location along the length of the catheter. For example, the first opening may be located proximal to the second opening. That is, the second opening may be located at or near the distal tip of the catheter, while the first opening is located at a position closer to the port. The first opening may also be substantially perpendicular to the second opening.


In another aspect, the present invention relates to a needle assembly, comprising at least one infusion needle and at least two aspiration needles. The at least one infusion needle is configured to penetrate the second septum of the second reservoir, while the at least two aspiration needles are configured to penetrate the first septum of the first reservoir (described above). The aspiration and infusion needles are, therefore, in fluid communication with the aspiration and infusion reservoirs, respectively. The at least one infusion needle and the at least two aspiration needles may include non-coring (i.e., Huber) needles. Needles of any size (i.e., gauge) may be used, for example, both the infusion and aspiration needles may be at least 19 gauge. To establish optimal fluid flow, the at least two aspiration needles may include openings that face in substantially opposite directions. Alternatively, the openings of the at least two aspiration needles may be configured such that they both face the inlet port of the aspiration reservoir. The at least two needles may be attached to each other, at for example, a y-site. The infusion needle may also include an opening configured to face the outlet port of the infusion reservoir. The at least two aspiration needles and at least one infusion needle allow the aspiration and infusion reservoirs to be in fluid communication with a blood circulation apparatus, such as an apheresis or hemodialysis machine.


In another embodiment, the present invention contemplates kits for the practice of the methods of this invention. The kits may include one or more containers containing a multi-reservoir implantable port, an aspiration needle assembly, an infusion needle assembly and catheter.


As used herein, “coring” refers to any portion of the septum that is forced into the shaft of a needle as the needle tip advances through the septum body. Septum coring produces small, detached particles that may become trapped in the cardiovascular system of the patient. In addition to potentially harming the patient, these particles can obstruct fluid flow through the needle assemblies and/or outlet stem of the multi-reservoir port. While a septum is capable of withstanding a certain number of coring events, continued coring creates a series of small passageways that extend through the body of the septum and eventually lead to various forms of septum failure. To at least partially address this problem, non-coring (e.g., Huber) needles are preferably used in conjunction with aspiration and infusion assemblies for accessing port reservoirs. Unlike traditional hypodermic needles, non-coring Huber needles pierce the septum in a knife-like fashion, thereby facilitating the resealing of the septum so that the aforementioned problems are largely averted.


As used herein, “trocar” refers to a surgical instrument having a sharpened point used to puncture a percutaneous surface for a variety of minimally invasive medical applications. In one embodiment, the body of the trocar includes a hollow tube through which a variety of medical instruments can be inserted into a patient's body. Alternatively, the body of the trocar can include a solid shaft, or sealed tube, dimensioned to fit within and reversibly occlude the lumen of a needle. The pointed tip of the trocar extends beyond, or is substantially flush with, the pointed end of the needle. Once the target surface (e.g., the skin, septum etc.) has been penetrated, the trocar is removed such that the lumen of the needle remains in fluid contact with the selected reservoir, chamber or body site.


As used herein, “durometer” refers to the measurement of a material's resistance to permanent indentation (i.e., hardness), and is typically used in reference to polymers, elastomers rubbers and the like. A material's durometer value can be determined by measuring the depth of an indentation in the material created by a given force on a standardized pressure foot. The depth of the indentation within the material is dependent on a variety of factors, including the density of the material, its viscoelastic properties, the shape of the pressure foot and the duration of the test.


As used herein, a “staggered tip” refers to a dual-lumen catheter that prevents fluid recirculation by positioning the entry site of the aspiration lumen away from the exit site of the infusion lumen (located at or near the catheter tip). Staggered-tip catheter designs are known in the art, including for example U.S. Pat. Nos. 8,317,773 and D603,044, herein incorporated by reference. The staggered tip design ensures that treated blood exiting the infusion lumen is carried away from the catheter tip as it re-enters circulation.


Other aspects, features, and advantages of the present invention are outlined in the detailed description, drawings, and claims.





BRIEF DESCRIPTION OF THE DRAWINGS

Non-limiting embodiments of the present disclosure will be described by way of example with reference to the accompanying figures, which are schematic and not intended to be drawn to scale. In the figures, each identical or nearly identical component illustrated is typically represented by a single numeral. For purposes of clarity, not every component is labeled in every figure, nor is every component of each embodiment of the disclosure shown where illustration is not necessary to allow those of ordinary skill in the art to understand the disclosure.



FIGS. 1A-C provide a top view of a multi-reservoir port system, in accordance with one embodiment of the present invention.



FIGS. 2A-B provides a schematic side-view of a staggered-tip catheter designs, in accordance with one embodiment of the present invention.



FIG. 3 provides a side-by-side comparison of the size of various gauge needles known in the art.



FIG. 4A provides a schematic view of a conventional 16 gauge trocar needle as recognized in the art.



FIG. 4B provides a schematic top-view of a three-legged insertion profile using the trocar of FIG. 4A.



FIG. 4C provides a schematic top view of overlapping three-legged insertion profiles using the trocar of FIG. 4A.



FIG. 4D depicts multiple and overlapping three-legged insertion sites through a septum using the trocar of FIG. 4A.



FIG. 4E depicts a magnified view of an overlapping three-legged insertion site of FIG. 4D.



FIG. 5A provides a schematic view of a rounded singular point trocar, in accordance with one embodiment of the present invention.



FIG. 5B provides a schematic side view a trocar that includes a unidirectional face, in accordance with one embodiment of the present invention.



FIG. 6A provides a schematic side view a needle aspiration and infusion system, in accordance with one embodiment of the present invention.



FIG. 6B provides a top view of an aspiration reservoir with vortex fluid flow, in accordance with one embodiment of the present invention.



FIGS. 7A-C provide schematic side views of needle shaft designs, in accordance with embodiments of the present invention.



FIGS. 8A-C provide a schematic illustrations of various multi-durometer septum designs, in accordance with one embodiment of the present invention.



FIGS. 9A-C provide a schematic side view of septum and port geometries, in accordance with embodiments of the present invention.



FIGS. 10A-D provide schematic illustration of various dual-lumen catheter designs, in accordance with one embodiment of the present invention.



FIG. 11 depicts the placement of a staggered-tip dual-lumen catheter within a patient, in accordance with one embodiment of the present invention.





DETAILED DESCRIPTION OF THE INVENTION

The present invention may be further understood with reference to the following description and the appended drawings, wherein like elements are referred to with the same reference numerals. The systems and methods of the present invention relate to multi-reservoir port, catheter and needle systems that support high-flow applications such as hemodialysis and apheresis. However, those skilled in the art will understand that the present invention is equally pertinent to a wide range of applications that benefit from the implantation of multi-reservoir ports with self-sealing septa, and which are accessible by a corresponding non-coring needle assembly.


As described herein, the present invention improves upon various components of conventional implantable port, needle-assembly and catheter designs to provide a system capable of maintaining balanced intraluminal fluid pressure required for high flow applications, without a corresponding decrease in septum puncture life. These advantages include 1) needle designs and configurations that provide optimal fluid flow and minimize damage to the septum, 2) dual-durometer septum designs and configurations that optimize self-sealing and minimize coring and 3) dual-lumen catheter designs and configurations that facilitate low pressure fluid flow within the aspiration lumen and prevent lumen constriction/collapsing. The cumulative effect that results from combining any, or all, of these improvements into a single system exceeds the improvements realized by an individually improvement alone. These improvements provide direct and immediate benefits to both the patient and medical professional. For example, the multi-reservoir ports decrease patient discomfort during implantation by requiring only a single invasive procedure, and are easier to conceal than separate single-reservoir ports implanted at different locations within the body. Patient discomfort is also decreased during treatment by limiting needle punctures through the skin to a single access site. Additionally, the ability to withstand a high number of needle punctures without septum failure allows expensive and invasive port replacement procedures to be postponed, or avoided altogether. This represents a significant savings in terms of medical costs, as well patient discomfort and risk exposure to.


Multi-reservoir ports typically used in situations that require multi-lumen access to the vascular system. Examples of multi-reservoir ports, including the manner of fabrication and method of use are described in U.S. Patent Publication Nos. 20130150811 and 20090118683, each of which is assigned to Angiodynamics, Inc. of Latham, N.Y., and are fully incorporated herein by reference. Referring to FIG. 1, in one embodiment the present invention provides a multi-reservoir port 20 of the present invention includes a housing 21 that defines an aspiration reservoir 22 and an infusion reservoir 24 (i.e., first and second reservoirs, respectively). The aspiration 22 and infusion 24 reservoirs are covered and sealed by a first 23 and second 25 elastomeric septum, respectively. Each septum generally comprises a flexible membrane selected for its ability to continually re-seal the port reservoir following repeated punctures by a needle. An inlet stem 26 that defines an inlet lumen (not shown) is in fluid communication with the aspiration reservoir 22, and an outlet stem 28 that defines an outlet lumen (not shown) is in fluid communication with the infusion reservoir 24. The inlet 26 and outlet 28 stems are dimensioned to receive the proximal end 32 (i.e., proximal tip) of a dual-lumen catheter 30.


Referring to FIG. 2, in one embodiment the dual-lumen catheter includes a proximal end 32 and a distal end 34, with aspiration 36 and infusion 38 lumens (i.e., first and second lumens, respectively) extending therebetween. The aspiration lumen 36 at the distal end 34 of catheter 30 includes an opening 36a dimensioned to receive the inlet stem 26 of the multi-reservoir port 20 (FIG. 1C), such that the proximal end 32 of the catheter 30 is in fluid communication with the aspiration reservoir 22. Similarly, the infusion lumen 38 at the distal end 34 of catheter 30 includes an opening 38a dimensioned to receive the outlet stem 28 of the multi-reservoir port 20 (FIG. 1C), such that the proximal end 32 of the catheter 30 is in fluid communication with the infusion reservoir 24. The proximal end 32 of the dual-lumen catheter 30 includes a proximal opening 36b of the aspiration lumen 36 that is located distal to the proximal opening 38b of the infusion lumen 38. Additional examples of dual-lumen catheters are described in U.S. Pat. Nos. 7,410,602 and 8,317,773, each of which is assigned to Angiodynamics, Inc. of Latham, N.Y., and are fully incorporated herein by reference.


Medical procedures such as apheresis or hemodialysis require the septa covering the aspiration and infusion reservoirs to be frequently and repetitively punctured with a needle. The cumulative damage resulting from these needle penetrations gradually degrades the elastomeric septum until it is eventually unable to re-seal itself. The number of punctures that a septum can withstand depends on the size of the port, the type of elastomeric material, the durometer of the elastomeric material and the size of needle(s). FIG. 3 provides a side-by-side comparison of the relative sizes of standard needles used for various medical procedures. As would be expected, larger gauge needles cause more damage and decrease the “puncture life” or “stick life” of the septum. A typical septum is able to withstand approximately 50-100 punctures by a 16 gauge needle before its integrity is compromised to the point that it must be replaced. By contrast, the same septum can withstand upwards of 500 punctures by a standard 19 gauge needle. Thus, while a 16 gauge needle may provide the fluid dynamics required for high flow rate procedures, the inherent reduction in septum puncture life is not sustainable for frequently repeated procedures such as apheresis and hemodialysis.



FIG. 4A depicts a standard 16 gauge trocar needle 40 that includes a pointed tip 42 with three sharp edges 44, 46, 48 that create three-legged insertion profile (FIG. 4B) when advanced through the surface of an elastomeric septum. As shown in FIG. 4C, a gap is created when the legs of one or more adjacent puncture sites overlap, increasing the likelihood of the septum leaking from that location. As shown in FIG. 4D and FIG. 4E (magnified), repeated punctures of an elastomeric septum with the trocar such as the one depicted in FIG. 4A create multiple overlapping puncture sites that eventually compromise the integrity of the septum. Referring to FIG. 5A, in one embodiment an improved trocar needle 50 replaces the sharp edges of the conventional trocar tip with a singular rounded point 52. Replacing the sharp/rigid cutting edges with a smooth pointed surface increases the puncture life of the septum by providing a reduced insertion profile that decreases the likelihood of adjacent puncture sites overlapping. Referring to FIG. 5B, in another embodiment an improved trocar design includes a unidirectional face 54 configured to mirror the bevel of the needle opening 56. When inserted into the shaft of the needle, the unidirectional face 54 at the tip of the trocar conforms to the bevel of the needle opening 56 to create a solid unitary pointed tip 58. Unlike the rounded trocar of FIG. 5A, in which the septum is punctured entirely by the trocar tip, the pointed tip depicted in FIG. 5B represents the combined points of the needle opening and trocar.


Referring to FIG. 6A, in one embodiment an infusion needle assembly 60 comprising two non-coring 19 gauge needles 64 for penetrating the septum of the aspiration reservoir 22 (not shown) and a single 19 or 20 gauge needle 62 for penetrating the septum of the infusion reservoir 24 (not shown). In one embodiment, the two non-coring 19 gauge needles are connected to each other by tubing that bifurcates to form a y-site such that a medical professional can simultaneously puncture the septum of the aspiration reservoir with both needles. The embodiment depicted in FIG. 6A is not intended to limit the arrangement, orientation, gauge or number of needles used to penetrate the septum of the aspiration or infusion reservoirs. Table 1 provides a comparison of the inner diameter (ID) of various needle sizes, along with the corresponding number of needles of each gauge required to meet the internal cross-sectional area of a 16 gauge needle. Any number and/or combination of needles in Table 1 can be used to access the aspiration and/or infusion lumens described herein, depending on the desired flow rate, clinical application and condition of the patient.














TABLE 1









Area
# of needles to



Needle Size
ID (in)
(in∧2)
equal 16 G Area









16 G
0.047
0.00694
1



17 G
0.042
0.00554
1.25



18 G
0.033
0.00342
2.03



19 G
0.027
0.00229
3.03



20 G
0.02375
0.00177
3.92



22 G
0.01625
0.00083
8.37










Although two non-coring 19 gauge needles provide less cross-sectional area than a single 16 gauge needle, the fluid pressure they achieve is sufficiently similar to that of 16 gauge needle to prevent the aspiration lumen from constricting and/or collapsing upon itself. The ability of two 19 gauge needles to achieve fluid pressures that maintain aspiration lumen integrity similar to one 16 gauge needle while providing a higher clinically acceptable number of septum punctures represents a significant clinical advantage for high flow procedures.


In one embodiment, fluid flow may be further optimized by adjusting the orientation of each needle opening (i.e., bevel) in the needle assembly depicted in FIG. 6A. Since the position of the multi-reservoir port is visible underneath the skin, the openings of the linked non-coring needles may be positioned such that they face directly towards the inlet lumen. Alternatively, as shown in FIG. 6B, in another embodiment the openings of the linked non-coring needles 64 (top view) are positioned such that they face in substantially opposite directions to facilitate vortex (i.e., spiral) flow within the aspiration reservoir. As described in U.S. Pat. No. 5,951,512 assigned to Angiodynamics, Inc. of Latham, N.Y., incorporated herein by reference, vortex flow within a port reservoir provides a number of benefits, including the prevention of unwanted buildup of blood components within the port reservoirs. As indicated by the direction of the arrows, facing the aspiration needles 64 such that their respective openings face opposite directions encourages the fluid to flow in a vortex pattern within the aspiration reservoir. The pattern of flow depicted in FIG. 6B allows fluid to flow into each needle opening from opposite, and therefore non-competing, portions of the circulating vortex. It should be appreciated that vortex flow can be established in both the aspiration reservoir (i.e., as fluid is drawn into the needle openings) and infusion reservoir (i.e., as fluid flows out of the needle openings) by adjusting the orientation of the needle opening(s) within the aspiration or infusion reservoir.


In yet another embodiment, flow rates through the aspiration and/or infusion needle assemblies can be further optimized by using needle shaft designs that reduce the pressure required to meet the desired flow rates. For example, the length of the small inner diameter of a needle of standard length and shape (FIG. 7A) can be minimized by providing a needle shaft that flares (FIG. 7B) or gradually tapers (FIG. 7C) to a wider inner diameter at a point above the needle tip, thereby reducing the pressure drop over the length of the needle. The wider portions of the needle shaft of FIGS. 7B and 7C are sufficiently distant from the pointed tip of the needle to cause minimal trauma to both the patient and port septum.


Since ports are fully implanted within the body, their service life is limited in large part by the durability (i.e., puncture life) of the septum. Septum puncture life, and therefore the life of the multi-reservoir port, can be optimized by careful selection of the septum material and the dimensions of the septum within the port assembly. Examples of needle-penetrable and self-sealable materials include, but are not limited to, silicone and related elastomeric materials. Regardless of the material used, after a threshold number of needle punctures the septum becomes damaged and is no longer able to re-seal itself. Once the integrity of the septum is compromised to the point that it can no longer prevent fluid leakage, either into or out of the port reservoir, it is necessary to replace the entire port assembly, and possibly the attached catheter as well. Generally, the ability of a septum to self-seal and resist coring is directly related to the durometer of the material it is constructed from. While low durometer materials tends to reduce coring, they are not as effective at self-sealing after withdrawal of the needle. Similarly, high durometer materials promote better self-sealing after needle withdrawal, but tend to core relatively easily. Due to these competing requirements, the septum of conventional implantable ports generally include elastomeric materials having a durometer that resists coring and is capable of self-sealing, but is not optimal for either criteria.


In another embodiment, the present invention provides a septum comprising a dual-durometer elastomeric material that includes one layer configured to minimize coring (i.e., a low durometer material) and a second layer configured for optimal self-sealing (i.e., a high durometer material). Optimizing the self-sealing and non-coring capabilities of the septum with a dual-durometer materials enhances flow rates throughout the system by allowing repeated penetration with large gauge needles. For example, as shown in FIG. 8A, a dual-durometer septum 80 can be formed during the molding process to preferably include a top layer 82 (i.e., the layer closest to the patient's skin) comprising a low durometer material to reduce coring, and a bottom layer 84 (i.e., the layer closest to the port reservoir) comprising a high durometer material to promote self-sealing. While the top and bottom layers of FIG. 8A are depicted as being of substantially the same thickness, it should be understood that the thickness and orientation of either layer may be adjusted according to the clinical application and needs of the patient. For example, as shown in FIG. 8B, a thin layer of a low durometer material 82 may enclose (i.e., surround, encapsulate, encase etc.) a proportionally thicker layer of a high durometer material 84. Alternatively, as shown in FIG. 8C, the layer of high durometer material 84 may be disposed between top and bottom layers of low durometer material 82.


In another embodiment, the dual-durometer characteristics of the multi-layer septum of FIGS. 9A-C may be achieved by applying varying degrees of radially inward compressive force along the height 92 of a single-layer septum to create high and low durometer regions throughout the length of the septum. Inward compression increases the ability of the septum to re-seal puncture sites by pushing the edges of puncture holes together. Portions of the septum that receive little, or no, inward compression provide improved self-sealing due to their decreased susceptibility to coring. In one embodiment, the radially compressive inward force is created by placing a septum having a constant cylindrical shape within a port housing that includes a varying inner diameter. For example, the port housing of FIG. 9A includes an inner wall 94 configured to exert a radially compressive inward force to the middle portion of the septum 96, and incrementally less compression along the top 97 and bottom 98 portions of the septum. Similar to the dual-durometer septum of FIG. 8C, the septum configuration of FIG. 9A provides a high durometer middle layer 96 disposed between low durometer top 97 and bottom 98 layers. The durometer gradient created by the port housing of FIG. 9A ensures that the self-sealing inner portion of the septum is surrounded by top and bottom layers that are increasingly resistant to coring (i.e., top and bottom surfaces). FIG. 9B illustrates another embodiment, in which a radially compressive inward force is applied primarily to the top 97 of the septum to provide a high durometer top layer and a low durometer bottom layer 98. In another embodiment, the radially compressive inward force results from placing a septum with a varying outer diameter (OD) within a port housing. For example, the septum of FIG. 9C includes a middle portion 96 that is wider than the top 97 and bottom 98 portions such that the port housing primarily compresses the middle portion 96 of the septum. Similar to the dual-durometer septum of FIG. 8C, the septum of FIG. 9C provides a high durometer middle layer 96 disposed between low durometer top 97 and bottom layers 98. The septum geometries and port housing geometries described herein are provided by way of non-limiting example. It should be appreciated that the present invention contemplates a variety of septum and port geometries beyond those disclosed herein.


In one embodiment, flow rates may be further optimized by providing a dual-lumen catheter that includes an aspiration lumen that is over-sized as compared to the infusion lumen. The larger diameter of the aspiration lumen ensures that fluid flows from the proximal end of the catheter to the aspiration reservoir under minimal pressure. An additional benefit of using a dual-lumen that includes differently shaped aspiration and infusion lumens is that it becomes practically impossible to connect the distal end of the catheter to the incorrect inlet or outlet stem. As illustrated in FIG. 10A, the aspiration 36 and infusion 38 lumens may both include D-shapes, with the aspiration lumen having a larger internal diameter than the infusion lumen. Alternatively, as illustrated in FIG. 10B, the dual-lumen catheter may include a substantially oblong aspiration lumen 36 and a concave infusion lumen 38. An over-sized aspiration lumen is particularly useful for hemodialysis procedures, which require flow rates of at least 400 ml/min. However, the over-sized aspiration lumens required for hemodialysis may be unnecessarily larger for the comparatively low 150 ml/min flow rates required for apheresis. Referring to FIGS. 10C and 10D, dual-lumen catheters may be designed specifically for apheresis that include aspiration 36 and infusion 38 lumens that are both substantially circular (i.e., round, oval, oblong, elliptical etc.). Circular shaped lumens remain capable of proving the flow rates required for apheresis and provide better structural support than D-shaped designs to prevent the aspiration lumen from collapsing under negative pressure. As discussed above, the integrity of the infusion lumen is not an issue because fluid flows though the infusion lumen under positive pressure. However, a dual-lumen catheter in which both lumens are substantially circular is still beneficial because medical professionals commonly reverse the aspiration and infusion lumens during treatment. For example, if the aspiration lumen has a fibrin sheath buildup or other blockage reversing the direction of flow such allows blockages to be flushed away (i.e., into circulation). Thus, it remains important to have an infusion lumen capable of withstanding the negative pressures associated with an aspiration lumen.


All of the systems, assemblies and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the present invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations can be applied to the systems, assemblies and/or methods described herein without departing from the concept, spirit and scope of the invention. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.


While embodiments of the invention have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the invention.

Claims
  • 1. A multi-reservoir port system, comprising: a vascular access port, including: a housing defining first and second reservoirs,a first septum mounted within the housing sealing the first reservoir, the first septum comprising an elastomeric material having a first septum first layer having a first durometer and a first septum second layer having a second durometer, the first septum second layer being encapsulated on all sides by the first septum first layer,a second septum mounted within the housing sealing the second reservoir, the second septum comprising an elastomeric material having a second septum first layer having a first durometer and a second septum second layer having a second durometer, the second septum second layer being encapsulated on all sides by the second septum first layer,an inlet stem having an inlet lumen in fluid communication with the first reservoir, andan outlet stem having an outlet lumen in fluid communication with the second reservoir; anda dual-lumen catheter having a proximal end, a distal end, and first and second lumens extending therebetween;wherein the inlet stem is dimensioned to receive the first lumen at the proximal end of the catheter; andwherein the outlet stem is dimensioned to receive the second lumen at the proximal end of the catheter.
  • 2. The assembly of claim 1, wherein the durometer of the first septum first layer and second septum first layer are less than the durometer of the first septum second layer and the second septum second layer.
  • 3. The assembly of claim 1, wherein the thickness of the first septum second layer and second septum second layer is greater than the thickness of the first septum first layer and second septum first layer.
  • 4. A multi-reservoir port and needle system, comprising: a vascular access port, including: a housing defining first and second reservoirs,a first septum mounted within the housing sealing the first reservoir, the first septum comprising an elastomeric material having a first septum first layer having a first durometer and a first septum second layer having a second durometer, the first septum second layer being encapsulated on all sides by the first septum first layer,a second septum mounted within the housing sealing the second reservoir, the second septum comprising an elastomeric material having a second septum first layer having a first durometer and a second septum second layer having a second durometer, the second septum second layer being encapsulated on all sides by the second septum first layer,an inlet stem having an inlet lumen in fluid communication with the first reservoir, andan outlet stem having an outlet lumen in fluid communication with the second reservoir; anda needle assembly, including: at least one infusion needle; andat least two aspiration needles wherein the at least two aspiration needles are attached to each other so as to be parallel of one another;wherein the infusion needle is configured to penetrate the second septum of the vascular access port, and the at least two aspiration needles are configured to penetrate the first septum of the vascular access port.
  • 5. The assembly of claim 4, wherein the at least one infusion needle and at least two aspiration needles are non-coring.
  • 6. The assembly of claim 4, wherein the at least one infusion needle and at least two aspiration needles are at least 19 gauge.
  • 7. The assembly of claim 4, wherein each of the at least two aspiration needles include openings that face in opposite directions.
  • 8. The assembly of claim 4, wherein the at least two aspiration needles are attached to each other.
  • 9. The assembly of claim 4, wherein the at least two aspiration needles are in fluid communication with the aspiration reservoir.
  • 10. The assembly of claim 4, wherein the infusion needle is in fluid communication with the infusion reservoir.
  • 11. The assembly of claim 4, wherein the at least one infusion needle and at least two aspiration needles are in fluid communication with a blood circulation apparatus.
  • 12. The assembly of claim 11, wherein the blood circulation apparatus includes a dialysis machine or an apheresis machine.
  • 13. A method of performing apheresis, comprising: implanting a multi-reservoir vascular access port, the multi-reservoir vascular access port comprising: a housing defining an aspiration reservoir and an infusion reservoirs,a first septum mounted within the housing sealing the aspiration reservoir, the first septum comprises an elastomeric material having a first septum first layer having a first durometer and a first septum second layer having a second durometer, the first septum second layer being encapsulated on all sides by the first septum first layer,a second septum mounted within the housing sealing the infusion reservoir, the second septum comprises an elastomeric material having a second septum first layer having a first durometer and a second septum second layer having a second durometer, the second septum second layer being encapsulated on all sides by the second septum first layer;accessing the aspiration reservoir of the multi-reservoir vascular access port with an aspiration needle assembly;accessing the infusion reservoir of the multi-reservoir vascular access port with an infusion needle assembly;flowing fluid from the aspiration reservoir through the aspiration needle assembly to an apheresis machine; andflowing fluid from the apheresis machine to the infusion reservoir through the infusion needle assembly.
  • 14. The method of claim 13, wherein the needles of the aspiration needle assembly and infusion needle assembly are non-coring 19 gauge needles.
US Referenced Citations (544)
Number Name Date Kind
1653819 Northcott et al. Dec 1927 A
3094124 Birtwell Jun 1963 A
3392183 Windemuth Jul 1968 A
3427366 Verdol et al. Feb 1969 A
3438375 Ericson Apr 1969 A
3872058 Gresham Mar 1975 A
3971376 Wichterle Jul 1976 A
3978157 Bottenbruch et al. Aug 1976 A
4016886 Doss et al. Apr 1977 A
4054139 Crossley Oct 1977 A
4142525 Binard et al. Mar 1979 A
4226246 Fragnet Oct 1980 A
4245635 Kontos Jan 1981 A
4248224 Jones Feb 1981 A
4262672 Kief Apr 1981 A
4309994 Grunwald Jan 1982 A
4312907 Hiraoka et al. Jan 1982 A
4403983 Edelman et al. Sep 1983 A
4405305 Stephen et al. Sep 1983 A
4407943 Cole et al. Oct 1983 A
4423740 Castle et al. Jan 1984 A
4425119 Berglund Jan 1984 A
4468224 Enzmann et al. Aug 1984 A
4469483 Becker et al. Sep 1984 A
4483688 Akiyama Nov 1984 A
4543088 Bootman et al. Sep 1985 A
4563180 Jervis et al. Jan 1986 A
4569673 Tesi Feb 1986 A
4571749 Fischell Feb 1986 A
4584362 Leckart et al. Apr 1986 A
4587954 Haber May 1986 A
4592920 Murtfeldt Jun 1986 A
4603152 Laurin et al. Jul 1986 A
4623327 Mahurkar Nov 1986 A
4645495 Vaillancourt Feb 1987 A
4661530 Gogolewski et al. Apr 1987 A
4673394 Fenton, Jr. et al. Jun 1987 A
4692146 Hilger Sep 1987 A
4710174 Moden et al. Dec 1987 A
4742090 Hunter et al. May 1988 A
4767410 Moden et al. Aug 1988 A
4769005 Ginsburg et al. Sep 1988 A
4778452 Moden et al. Oct 1988 A
4781680 Redmond et al. Nov 1988 A
4781695 Dalton Nov 1988 A
4788083 Dammann et al. Nov 1988 A
4792354 Matsuo et al. Dec 1988 A
4804359 Grunwald et al. Feb 1989 A
4808156 Dean Feb 1989 A
4810963 Blake-Coleman et al. Mar 1989 A
4822341 Colone Apr 1989 A
4838269 Robinson et al. Jun 1989 A
4838873 Landskron et al. Jun 1989 A
4857053 Dalton Aug 1989 A
4861830 Ward, Jr. Aug 1989 A
4886501 Johnston et al. Dec 1989 A
4886502 Poirier et al. Dec 1989 A
4892518 Cupp et al. Jan 1990 A
4897081 Poirier et al. Jan 1990 A
4902503 Umemura et al. Feb 1990 A
4907601 Frick Mar 1990 A
4929236 Sampson May 1990 A
4944726 Hilal et al. Jul 1990 A
4946793 Marshall, III Aug 1990 A
4954130 Edwards Sep 1990 A
4955861 Enegren et al. Sep 1990 A
4966586 Vaillancourt Oct 1990 A
4983162 Metais et al. Jan 1991 A
4994503 Harris et al. Feb 1991 A
4999210 Solomon et al. Mar 1991 A
5013304 Russell et al. May 1991 A
5019034 Weaver et al. May 1991 A
5019096 Fox, Jr. et al. May 1991 A
5041098 Loiterman et al. Aug 1991 A
5052391 Silberstone et al. Oct 1991 A
5053013 Ensminger et al. Oct 1991 A
5053023 Martin Oct 1991 A
5053423 Liu Oct 1991 A
5058605 Slovak Oct 1991 A
5059170 Cameron Oct 1991 A
5064871 Sciangola Nov 1991 A
5069206 Crosbie Dec 1991 A
5084015 Moriuchi Jan 1992 A
5092849 Sampson Mar 1992 A
5098843 Calvin Mar 1992 A
5125893 Dryden Jun 1992 A
5129887 Euteneuer et al. Jul 1992 A
5129891 Young Jul 1992 A
5133742 Pinchuk Jul 1992 A
5134070 Casnig Jul 1992 A
5137529 Watson et al. Aug 1992 A
5145727 Potts et al. Sep 1992 A
5149576 Potts et al. Sep 1992 A
5151231 Lambert et al. Sep 1992 A
5167638 Felix et al. Dec 1992 A
5171305 Schickling et al. Dec 1992 A
5173158 Schmukler Dec 1992 A
5178612 Fenton, Jr. Jan 1993 A
5180365 Ensminger et al. Jan 1993 A
5193537 Freeman Mar 1993 A
5203771 Melker et al. Apr 1993 A
5205834 Moorehead et al. Apr 1993 A
5213574 Tucker May 1993 A
D337637 Tucker Jul 1993 S
5229431 Pinchuk Jul 1993 A
5236417 Wallis Aug 1993 A
5240675 Wilk et al. Aug 1993 A
5242415 Kantrowitz et al. Sep 1993 A
5242995 Kim et al. Sep 1993 A
5249598 Schmidt Oct 1993 A
5250038 Melker et al. Oct 1993 A
5260020 Wilk et al. Nov 1993 A
5263930 Ensminger Nov 1993 A
5273525 Hofmann Dec 1993 A
5281199 Ensminger et al. Jan 1994 A
5281205 McPherson Jan 1994 A
5283194 Schmukler Feb 1994 A
5300048 Drewes, Jr. et al. Apr 1994 A
5312337 Flaherty et al. May 1994 A
5318545 Tucker Jun 1994 A
5318563 Malis et al. Jun 1994 A
5328451 Davis et al. Jul 1994 A
5330449 Prichard et al. Jul 1994 A
5334171 Kaldany Aug 1994 A
5350360 Ensminger et al. Sep 1994 A
5352204 Ensminger Oct 1994 A
5356381 Ensminger et al. Oct 1994 A
5370624 Edwards et al. Dec 1994 A
5372582 Skrabal et al. Dec 1994 A
5373855 Skrabal et al. Dec 1994 A
5387192 Glantz et al. Feb 1995 A
5389069 Weaver Feb 1995 A
5395525 Takano et al. Mar 1995 A
5399168 Wadsworth, Jr. et al. Mar 1995 A
5403291 Abrahamson Apr 1995 A
5403311 Abele et al. Apr 1995 A
5405340 Fageol et al. Apr 1995 A
5417656 Ensminger et al. May 1995 A
5421814 Geary Jun 1995 A
5423334 Jordan Jun 1995 A
5425752 Vu'Nguyen Jun 1995 A
5439440 Hofmann Aug 1995 A
5445608 Chen et al. Aug 1995 A
5458582 Nakao Oct 1995 A
5458625 Kendall Oct 1995 A
5476451 Ensminger et al. Dec 1995 A
5486570 St. Clair Jan 1996 A
5509897 Twardowski et al. Apr 1996 A
5514127 Shanks May 1996 A
5520632 Leveen et al. May 1996 A
5520643 Ensminger et al. May 1996 A
5527277 Ensminger et al. Jun 1996 A
5527278 Ensminger et al. Jun 1996 A
5527307 Srisathapat et al. Jun 1996 A
5531684 Ensminger et al. Jul 1996 A
5533999 Hood et al. Jul 1996 A
5536240 Edwards et al. Jul 1996 A
5542200 Matsuoka Aug 1996 A
5542923 Ensminger et al. Aug 1996 A
5542937 Chee et al. Aug 1996 A
5543200 Hargis et al. Aug 1996 A
5549576 Patterson et al. Aug 1996 A
5554117 Ensminger et al. Sep 1996 A
5556381 Ensminger et al. Sep 1996 A
5558641 Glantz et al. Sep 1996 A
5562617 Finch, Jr. et al. Oct 1996 A
5562618 Cai et al. Oct 1996 A
5569182 Twardowski et al. Oct 1996 A
5571152 Chen et al. Nov 1996 A
5575769 Vaillancourt Nov 1996 A
5575811 Reid et al. Nov 1996 A
5589563 Ward et al. Dec 1996 A
5607393 Ensminger et al. Mar 1997 A
5613945 Cai et al. Mar 1997 A
5613974 Andreas et al. Mar 1997 A
5614136 Pepin et al. Mar 1997 A
5626146 Barber et al. May 1997 A
5634899 Shapland et al. Jun 1997 A
5637877 Sinofsky Jun 1997 A
5643197 Brucker et al. Jul 1997 A
5647859 Lampropoulos et al. Jul 1997 A
RE35601 Eckenhoff Sep 1997 E
5662616 Bousquet Sep 1997 A
5662913 Capelli Sep 1997 A
5674267 Mir et al. Oct 1997 A
5676656 Brimhall Oct 1997 A
5681289 Wilcox et al. Oct 1997 A
5695482 Kaldany Dec 1997 A
5695490 Flaherty et al. Dec 1997 A
5702359 Hofmann et al. Dec 1997 A
5702363 Flaherty Dec 1997 A
5702754 Zhong Dec 1997 A
5704915 Melsky et al. Jan 1998 A
5713844 Peyman Feb 1998 A
5720921 Meserol Feb 1998 A
5723718 Berens Mar 1998 A
5725510 Hartmann et al. Mar 1998 A
5741228 Lambrecht et al. Apr 1998 A
5776096 Fields Jul 1998 A
5778894 Dorogi et al. Jul 1998 A
5779897 Kalthod et al. Jul 1998 A
5782882 Lerman et al. Jul 1998 A
5792104 Speckman et al. Aug 1998 A
5792123 Ensminger Aug 1998 A
5795326 Siman Aug 1998 A
5797886 Roth et al. Aug 1998 A
5800378 Edwards et al. Sep 1998 A
5800414 Cazal Sep 1998 A
5810762 Hofmann Sep 1998 A
5810776 Bacich et al. Sep 1998 A
5810789 Powers et al. Sep 1998 A
5817072 Lampropoulos et al. Oct 1998 A
5830172 Leveen et al. Nov 1998 A
5830196 Hicks Nov 1998 A
5830526 Wilson et al. Nov 1998 A
5833654 Powers et al. Nov 1998 A
5836905 Lemelson et al. Nov 1998 A
5836935 Ashton et al. Nov 1998 A
5840063 Flaherty Nov 1998 A
5843026 Edwards et al. Dec 1998 A
5855203 Matter Jan 1999 A
5873849 Bernard Feb 1999 A
5876366 Dykstra et al. Mar 1999 A
5879322 Lattin et al. Mar 1999 A
5879333 Smith Mar 1999 A
5879499 Corvi Mar 1999 A
5882341 Bousquet Mar 1999 A
5902279 Powles May 1999 A
5906596 Tallarida May 1999 A
5908701 Jennings et al. Jun 1999 A
5919142 Boone et al. Jul 1999 A
5928174 Gibbins Jul 1999 A
5929201 Gibbons et al. Jul 1999 A
5944688 Lois Aug 1999 A
5947889 Hehrlein Sep 1999 A
5951512 Dalton Sep 1999 A
5954691 Prosl Sep 1999 A
5954966 Matsuura et al. Sep 1999 A
5957890 Mann et al. Sep 1999 A
5967490 Pike Oct 1999 A
5983131 Weaver et al. Nov 1999 A
5989216 Johnson et al. Nov 1999 A
5991697 Nelson et al. Nov 1999 A
5999847 Elstrom Dec 1999 A
6001079 Pourchez Dec 1999 A
6001080 Kuracina et al. Dec 1999 A
6009347 Hofmann Dec 1999 A
6010613 Walters et al. Jan 2000 A
6016452 Kasevich Jan 2000 A
6030411 Lawandy Feb 2000 A
6033393 Balbierz et al. Mar 2000 A
6039712 Fogarty Mar 2000 A
6041252 Walker et al. Mar 2000 A
6055453 Hofmann et al. Apr 2000 A
6068650 Hofmann et al. May 2000 A
6085115 Weaver et al. Jul 2000 A
6086555 Eliasen et al. Jul 2000 A
6090106 Goble et al. Jul 2000 A
6093180 Elsberry Jul 2000 A
6099508 Bousquet Aug 2000 A
6102884 Squitieri Aug 2000 A
6102885 Bass Aug 2000 A
6106521 Blewett et al. Aug 2000 A
6109270 Mah et al. Aug 2000 A
6111049 Sendijarevic et al. Aug 2000 A
6120492 Finch et al. Sep 2000 A
6122599 Mehta Sep 2000 A
6127485 Klun et al. Oct 2000 A
6127507 Santerre Oct 2000 A
6132416 Broselow Oct 2000 A
6132419 Hofmann Oct 2000 A
6159163 Strauss et al. Dec 2000 A
6177522 Brady et al. Jan 2001 B1
6197845 Janssen et al. Mar 2001 B1
6197846 Combe et al. Mar 2001 B1
6200338 Solomon et al. Mar 2001 B1
6208893 Hofmann Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6212433 Behl Apr 2001 B1
6213973 Eliasen et al. Apr 2001 B1
6213995 Steen et al. Apr 2001 B1
6216034 Hofmann et al. Apr 2001 B1
6217566 Ju et al. Apr 2001 B1
6219577 Brown, III et al. Apr 2001 B1
6227200 Crump et al. May 2001 B1
6228088 Miller et al. May 2001 B1
6241702 Lundquist et al. Jun 2001 B1
6245039 Brugger et al. Jun 2001 B1
6254645 Kellis, Jr. et al. Jul 2001 B1
6261831 Agee Jul 2001 B1
6273404 Holman et al. Aug 2001 B1
6278895 Bernard Aug 2001 B1
6280423 Davey et al. Aug 2001 B1
6300108 Rubinsky et al. Oct 2001 B1
6326177 Schoenbach et al. Dec 2001 B1
6347247 Dev et al. Feb 2002 B1
6349233 Adams Feb 2002 B1
6351674 Silverstone Feb 2002 B2
6353057 He et al. Mar 2002 B1
6355020 Bousquet Mar 2002 B1
6355858 Gibbins Mar 2002 B1
6368658 Schwarz et al. Apr 2002 B1
6375637 Campbell et al. Apr 2002 B1
6387105 Gifford, III et al. May 2002 B1
6387671 Rubinsky et al. May 2002 B1
6403348 Rubinsky et al. Jun 2002 B1
6409700 Siegel, Jr. et al. Jun 2002 B1
6419643 Shimada et al. Jul 2002 B1
6419674 Bowser et al. Jul 2002 B1
6428513 Abrahamson Aug 2002 B1
6442415 Bis et al. Aug 2002 B1
6446671 Armenia et al. Sep 2002 B2
6448364 Clatty et al. Sep 2002 B1
6461568 Eckhardt Oct 2002 B1
6461569 Boudreaux Oct 2002 B1
6470211 Ideker et al. Oct 2002 B1
6482619 Rubinsky et al. Nov 2002 B1
6493592 Leonard et al. Dec 2002 B1
6500173 Underwood et al. Dec 2002 B2
6517520 Chang et al. Feb 2003 B2
6526320 Mitchell Feb 2003 B2
6530951 Bates et al. Mar 2003 B1
6545097 Pinchuk et al. Apr 2003 B2
6551346 Crossley Apr 2003 B2
6562604 Rubinsky et al. May 2003 B2
6575959 Sarge et al. Jun 2003 B1
6592544 Mooney et al. Jul 2003 B1
6595966 Davey et al. Jul 2003 B2
6605075 Burdulis Aug 2003 B1
6605751 Gibbins et al. Aug 2003 B1
6607529 Jones et al. Aug 2003 B1
6610046 Usami et al. Aug 2003 B1
6611706 Avrahami et al. Aug 2003 B2
6613211 McCormick et al. Sep 2003 B1
6627421 Unger et al. Sep 2003 B1
6629950 Levin Oct 2003 B1
6630086 Goral et al. Oct 2003 B1
6638252 Moulton et al. Oct 2003 B2
6645230 Whitehurst Nov 2003 B2
6653091 Dunn et al. Nov 2003 B1
6669691 Taimisto Dec 2003 B1
6692493 McGovern et al. Feb 2004 B2
6693093 Chowdhary et al. Feb 2004 B2
6697669 Dev et al. Feb 2004 B2
6697670 Chomenky et al. Feb 2004 B2
6702808 Kreindel Mar 2004 B1
6719727 Brimhall et al. Apr 2004 B2
6730113 Eckhardt et al. May 2004 B2
6777466 Eckstein et al. Aug 2004 B2
6795728 Chornenky et al. Sep 2004 B2
6801804 Miller et al. Oct 2004 B2
6819951 Patel et al. Nov 2004 B2
6827710 Mooney et al. Dec 2004 B1
6865416 Dev et al. Mar 2005 B2
6892099 Jaafar et al. May 2005 B2
6897349 Gibbins et al. May 2005 B2
6912417 Bernard et al. Jun 2005 B1
6927049 Rubinsky et al. Aug 2005 B2
6929631 Brugger et al. Aug 2005 B1
6938668 Whicher et al. Sep 2005 B2
6939357 Navarro et al. Sep 2005 B2
6962580 Adams et al. Nov 2005 B2
6962587 Johnson et al. Nov 2005 B2
6969381 Voorhees Nov 2005 B2
6972014 Eum et al. Dec 2005 B2
6994706 Chornenky et al. Feb 2006 B2
6997914 Smith et al. Feb 2006 B2
7053063 Rubinsky et al. May 2006 B2
7063698 Whayne et al. Jun 2006 B2
7070591 Adams et al. Jul 2006 B2
7130697 Chornenky et al. Oct 2006 B2
7179849 Terry Feb 2007 B2
7186239 Woehr Mar 2007 B2
7211083 Chornenky et al. May 2007 B2
7261708 Raulerson Aug 2007 B2
7264858 Belliveau et al. Sep 2007 B2
7267676 Chornenky et al. Sep 2007 B2
7351233 Parks Apr 2008 B2
7410602 Davey et al. Aug 2008 B2
7731700 Schytte Jun 2010 B1
7785302 Powers Aug 2010 B2
7947022 Amin et al. May 2011 B2
7959615 Stats et al. Jun 2011 B2
8021324 Bizup et al. Sep 2011 B2
8025639 Powers et al. Sep 2011 B2
8029482 Maniar et al. Oct 2011 B2
8071683 Mullick et al. Dec 2011 B2
8177762 Beasley et al. May 2012 B2
8178620 Mullick et al. May 2012 B2
8187234 Weaver et al. May 2012 B2
8202259 Evans et al. Jun 2012 B2
8257325 Schweikert et al. Sep 2012 B2
8267915 Daly et al. Sep 2012 B2
8317773 Appling et al. Nov 2012 B2
8318867 Mullick et al. Nov 2012 B2
8338537 Mullick et al. Dec 2012 B2
D676955 Orome Feb 2013 S
8377011 Weaver et al. Feb 2013 B2
8382723 Powers et al. Feb 2013 B2
8382724 Maniar et al. Feb 2013 B2
20010016717 Haarala et al. Aug 2001 A1
20010044596 Jaafar Nov 2001 A1
20010047195 Crossley Nov 2001 A1
20010056266 Tallarida et al. Dec 2001 A1
20020010491 Schoenbach et al. Jan 2002 A1
20020055731 Atala et al. May 2002 A1
20020077676 Schroeppel et al. Jun 2002 A1
20020082559 Chang et al. Jun 2002 A1
20020091362 Maginot et al. Jul 2002 A1
20020099323 Dev et al. Jul 2002 A1
20020138068 Watson et al. Sep 2002 A1
20020138117 Son Sep 2002 A1
20020165594 Biel Nov 2002 A1
20020193831 Smith Dec 2002 A1
20030009110 Tu et al. Jan 2003 A1
20030017073 Eckhardt et al. Jan 2003 A1
20030060856 Chornenky et al. Mar 2003 A1
20030065355 Weber Apr 2003 A1
20030088189 Tu et al. May 2003 A1
20030109871 Johnson et al. Jun 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030135168 Benchetrit Jul 2003 A1
20030170898 Gundersen et al. Sep 2003 A1
20030194433 Hei et al. Oct 2003 A1
20030203991 Schottman et al. Oct 2003 A1
20030208200 Palanker et al. Nov 2003 A1
20030220628 Klisch et al. Nov 2003 A1
20030225360 Eppstein et al. Dec 2003 A1
20040019371 Jaafar et al. Jan 2004 A1
20040034398 Eckhardt et al. Feb 2004 A1
20040059389 Chornenky et al. Mar 2004 A1
20040064086 Gottlieb et al. Apr 2004 A1
20040068241 Fischer Apr 2004 A1
20040068251 Chan et al. Apr 2004 A1
20040068315 Chandrasekaran et al. Apr 2004 A1
20040073171 Rogers et al. Apr 2004 A1
20040076582 Dimatteo et al. Apr 2004 A1
20040116965 Falkenberg Jun 2004 A1
20040121175 Flexman et al. Jun 2004 A1
20040131863 Belliveau et al. Jul 2004 A1
20040133173 Edoga et al. Jul 2004 A1
20040146877 Diss et al. Jul 2004 A1
20040153057 Davison Aug 2004 A1
20040167463 Zawacki et al. Aug 2004 A1
20040171747 Zhong Sep 2004 A1
20040199128 Morris et al. Oct 2004 A1
20040204691 Yashiro et al. Oct 2004 A1
20040243103 King et al. Dec 2004 A1
20040243107 Macoviak et al. Dec 2004 A1
20040267189 Mayor et al. Dec 2004 A1
20050010275 Sahatjian et al. Jan 2005 A1
20050013988 Fu et al. Jan 2005 A1
20050033237 Fentress et al. Feb 2005 A1
20050043726 McHale et al. Feb 2005 A1
20050049541 Behar et al. Mar 2005 A1
20050059958 Lessard et al. Mar 2005 A1
20050104255 Mejlhede et al. May 2005 A1
20050119724 Phaneuf et al. Jun 2005 A1
20050124980 Sanders Jun 2005 A1
20050131356 Ash et al. Jun 2005 A1
20050137580 Raulerson et al. Jun 2005 A1
20050143817 Hunter et al. Jun 2005 A1
20050165393 Eppstein Jul 2005 A1
20050171490 Weaver et al. Aug 2005 A1
20050171510 DiCarlo et al. Aug 2005 A1
20050171523 Rubinsky et al. Aug 2005 A1
20050171574 Rubinsky et al. Aug 2005 A1
20050176893 Rana et al. Aug 2005 A1
20050182352 DiMatteo et al. Aug 2005 A1
20050182462 Chornenky et al. Aug 2005 A1
20050192546 Griego et al. Sep 2005 A1
20050197619 Rule et al. Sep 2005 A1
20050216074 Sahatjian et al. Sep 2005 A1
20050240080 Diekmann et al. Oct 2005 A1
20050256461 DiFiore et al. Nov 2005 A1
20050261636 Rome et al. Nov 2005 A1
20050261672 Deem et al. Nov 2005 A1
20050288730 Deem et al. Dec 2005 A1
20060004325 Hamatake et al. Jan 2006 A1
20060015086 Rasmussen et al. Jan 2006 A1
20060015147 Persson et al. Jan 2006 A1
20060025760 Podhajsky Feb 2006 A1
20060052757 Fischer et al. Mar 2006 A1
20060064159 Porter et al. Mar 2006 A1
20060079883 Elmouelhi et al. Apr 2006 A1
20060100592 Eliasen May 2006 A1
20060121610 Rubinsky et al. Jun 2006 A1
20060178648 Barron et al. Aug 2006 A1
20060189922 Amarasinghe et al. Aug 2006 A1
20060212078 Demarais et al. Sep 2006 A1
20060217703 Chornenky et al. Sep 2006 A1
20060247584 Sheetz et al. Nov 2006 A1
20060264752 Rubinsky et al. Nov 2006 A1
20060264833 Moulton Nov 2006 A1
20060293730 Rubinsky et al. Dec 2006 A1
20070037891 Esfand et al. Feb 2007 A1
20070043345 Davalos et al. Feb 2007 A1
20070060989 Deem et al. Mar 2007 A1
20070078385 Accisano et al. Apr 2007 A1
20070078391 Wortley et al. Apr 2007 A1
20070118069 Persson et al. May 2007 A1
20070161940 Blanchard et al. Jul 2007 A1
20070167925 Jacqmein Jul 2007 A1
20070191771 Moyer Aug 2007 A1
20070219497 Johnson et al. Sep 2007 A1
20070239099 Goldfarb et al. Oct 2007 A1
20070255237 Lobl et al. Nov 2007 A1
20070260221 Chesnin Nov 2007 A1
20070270754 Soderholm et al. Nov 2007 A1
20070287967 Hekmat et al. Dec 2007 A1
20080052786 Lin et al. Feb 2008 A1
20080108975 Appling et al. May 2008 A1
20080154186 Appling et al. Jun 2008 A1
20080228253 Mullick et al. Sep 2008 A1
20080234659 Cheng et al. Sep 2008 A1
20080294111 Tal et al. Nov 2008 A1
20080306465 Bailey et al. Dec 2008 A1
20090036768 Seehusen et al. Feb 2009 A1
20090118683 Hanson May 2009 A1
20090171319 Guo et al. Jul 2009 A1
20090171436 Casanova et al. Jul 2009 A1
20090204074 Powers et al. Aug 2009 A1
20090211968 Ho et al. Aug 2009 A1
20090216216 Powers et al. Aug 2009 A1
20090306606 Lancette et al. Dec 2009 A1
20090326515 Kagan Dec 2009 A1
20100049147 Tanikawa et al. Feb 2010 A1
20100106094 Fisher et al. Apr 2010 A1
20100191165 Appling et al. Jul 2010 A1
20110009799 Mullick et al. Jan 2011 A1
20110071500 Lareau Mar 2011 A1
20110098662 Zinn Apr 2011 A1
20110160673 Magalich et al. Jun 2011 A1
20110184353 DeMaria Jul 2011 A1
20110207893 Mullick et al. Aug 2011 A1
20110264058 Linden et al. Oct 2011 A1
20120053512 Muse Mar 2012 A1
20120095440 Islam Apr 2012 A1
20120148774 Mullick et al. Jun 2012 A1
20120184925 Grant Jul 2012 A1
20120220724 Mullick et al. Aug 2012 A1
20120232472 Bhagchandani et al. Sep 2012 A1
20130060200 Dalton et al. Mar 2013 A1
20130102962 Shih Apr 2013 A1
Foreign Referenced Citations (15)
Number Date Country
4000893 Jul 1991 DE
0378132 Jul 1990 EP
0670169 Jul 1990 EP
0935482 Aug 1999 EP
WO9639531 Dec 1996 WO
WO9818506 May 1998 WO
WO0020554 Apr 2000 WO
WO0107583 Feb 2001 WO
WO0107584 Feb 2001 WO
WO0107585 Feb 2001 WO
WO0181533 Nov 2001 WO
WO0187416 Nov 2001 WO
WO02102421 Dec 2002 WO
WO2004037341 May 2004 WO
WO2005065284 May 2004 WO
Non-Patent Literature Citations (54)
Entry
Guiffant, et al, Impact of the Shape of the Implantable Ports on their Efficiency of flow (Injection and Flushing), Medical Devices: Evidence and Research 2014:7, pp. 319-324.
Chand, et al, Use of Vascular Ports for Long-Term Apheresis in Children, J Vasc Interv Radiol 2015, 26: 1669-1672.
Shrestha, et al, Use of a Dual Lumen Port for Automated Red Cell Exchange in Adults with Sickle Cell Disease, Journal of Clinical Apheresis, 2015.
Sails et al., Can Peripherally Inserted Central Catheters be Used for Contrast Injection with a CT Power Injector?, JVIR vol. 13, Issue 2, Feb. 2002, Supplement S1.
Garland et al., Measurement of Extravascular Lung Water in Hemodialysis Patients Using Blood Ultrasound Velocity and Optical Density Dilution, American Society of Artificial Internal Organs Journal, 2002, pp. 398-403.
Teichgraber et al., Central Venous Access Catheters: Radiological Management of Complications, Cardiovascular and Interventional Radiology, Jul. 31, 2003, pp. 321-333.
Glickman et al., Challenges of hemodialysis access for high risk patients: Impact of mesenteric vein bioprosthetic graft, The Journal of Vascular Access, 2003 pp. 73-80.
Choi et al., Peritoneal Dialysis, Medicine, 2003, pp. 70-73.
Scher et al., Alternative Graft Materials for Hemodialysis Access, Seminars in Vascular Surgery, vol. 17, No. 1, Mar. 2004, pp. 19-24.
Wentling, Hemodialysis Catheters: Materials, Design and Manufacturing, Hemodialysis Vascular Access and Peritoneal Dialysis Access, vol. 142, 2004, pp. 112-127.
Siegman-Igra et al, Diagnosis of Vascular Catheter-Related Bloodstream Infection: a Meta-Analysis, Journal of Clinical Microbiology, vol. 35, No. 4, Apr. 1997, pp. 928-936.
Kindgen-Milles et al, Assessment of Temporary Dialysis Catheter Performance on the Basis of Flow and Pressure Measurements In Vivo and In Vitro, ASAIO Journal, 2007, pp. 351-356.
Spector et al., Clinincal Outcome of the Tal Palindrome Chronic Hemodialysis Catheter: Single Institution Experience, Journal of Vascular Interventional Radiology, vol. 19, No. 10, 2008, pp. 1434-1438.
Nael et al., Endovascular Management of Central Thoracic Veno-Occlusive Diseases in Hemodialysis Patients: A Single Institutional Experience in 69 Consecutive Patients, Journal of Vascular Interventional Radiology, vol. 20, No. 1, 2009, pp. 46-51.
Saad et al., Dual-Tract Transhepatic U-shaped Hemodialysis Inferior Vena Cava Catheter: A Feasibility Study in a Swine Model, Journal of Vascular Interventional Radiology, vol. 20, No. 12, Dec. 2009, pp. 1625-1631.
Witowski et al., Peritoneal Dialysis: A Biological Membrane with a Nonbiological Fluid, Biology of Peritoneal Membrane, 2009, pp. 27-34.
Cavallini et al., Substituting Citrate for Lactate in Peritoneal Dialysis Fluid Improves Ultrafiltration in Rats, Peritoneal Dialysis International, vol. 29, Jan. 2009, pp. 36-43.
Chan et al., Tunneled Dialysis Catheters: Recent Trends and Future Directions, Advances in Chronic Kidney Disease, vol. 16, No. 5, Sep. 2009, pp. 386-395.
Olinger et al., Acute clinical hypocalcemic myocardial depression during rapid blood transfusion and postoperative hemodialysis: A preventable complication, The Journal of Thoracic and Cardiovascular Surgery, vol. 72, No. 4, Oct. 1976, pp. 503-511.
McCarthy, et al, The Use of a Flow Rate Injetor for Contrast-Enhanced CT, Radiology, 1984, 151:800.
Ireland, et al, Safety and Convenience of a Mechanical Injector Pump for Conorary Angiography, Catheterization and Cardiovascular Diagnosis, 1989, 16:199-201.
Miles, et al, Safe use of an Intravenous Power Injector for CT: Experience and Protocol, RSNA, 1990, pp. 69-70.
Carlson, et al, Safety Considerations in the Power Injection of Contrast Media Via Central Venous Catheters During Computed Tomographic Examinations, Investigative Radiology vol. 27, 1992, pp. 337-340.
Steinbach, et al, Breast Implants, Common Complications, and Concurrent Breast Disease, RadioGraphics 1993, 13:95-118.
Vergara, Adverse Reactions to Contrast Media in CT: Effects of Temperature and Ionic Property, Radiology 1996, 199:363-366.
Herts, et al, Power Injection of Contrast Material through Central Venous Catheters for CT: In Vitro Evaluation, Radiology 1996, 200:731-735.
Kaste, et al, Safe Use of Power Injectors with Central and Peripheral Venous Access Devices for Pediatric CT, Pediatr Radiol, 1996, 36:499-501.
Urquiola, et al, Using Lead Foil as a Radiopaque Marker for Computerized Tomography Imaging when Implant Treatment Planning, Journal of Prosthetic Dentistry vol. 77 No. 2, 1997, pp. 227-228.
Hills, et al, Experience with 100 Consecutive Central Venous Access Arm Ports Placed by Interventional Radiologists, JVIR 1997, 8:983-989.
Ruess, et al, In-line Pressures Generated in Small-Bore Central Venous Catheters During Power Injection of CT Contrast Media, Radiology 1997, 203:625-629.
Blot, et al, Accuracy of Totally Implanted ports, tunnelled, single and multiple-lumen contral venous catheters for measurement of central venous pressure, Intensive Care Med, 2000, pp. 1837-1842.
Biffi, et al, A Randomized, Prospective Trial of Central Venous Ports Connected to Standard Open-Ended or Groshong Catheters in Adult Oncology Patients, American Cancer Society, 2001, pp. 1204-1212.
Funaki, Central Venous Access: A Primer for the Diagnostic Radiologist, AJR: 179, 2002, pp. 309-318.
Teichgraber, et al, Central Venous Access Catheters: Radiological Management of Complications, Cardiovasc Intervent Radiol, 2003, 26:321-333.
Costa, More Than Skin Deep: An Overview of Iodinated Contrast Media, JAVA vol. 8 No. 4, 2003, pp. 34-39.
Scher, et al, Alternative Graft Materials for Hemodialysis Access, Seminars in Vascular Surgery, vol. 17 No. 1, 2004, pp. 19-24.
Abstracts of the World Apheresis Association 10th Congress, Jornal of Clinical Apheresis, 2004, 18: 20-58.
Sanelli, Safety and Feasibility of Using a Central Venous Catheter for Rapid Contrast Injection Rates, AJR 183, 2004, pp. 1829-1834.
Swindle, et al, Vascular Access Port Usage in Large Animal Species, Contemporary Topics, 2005 vol. 44 No. 27 pp. 7-17.
Gebauer, Contrast Media Pressure Injectoin Using a Portal Catheter System—Results of an in Vitro Study, ROFO 2005, pp. 1417-1423.
Hou, et al, Comparisons of Outcomes and Survivals for Two Central Venous Access Port Systems, Journal of Surg Oncology, 2005, 91:61-66.
Swerdlow, Red Cell Exchange in Sickle Cell Disease, American Society of Hematology, 2006, pp. 48-53.
Supplement to Imaging Economics, CIN Strategies: Anticipate, Manage, Prevent, 2007, S1-S18.
Medtronic Synchromed II & Synchromed EL Priming Bolus Reference Card, 2007.
International Search Report PCT-US-99-03982_ISR dated Jul. 14, 1999.
International Search Report PCT-US-08-061447_IPRP dated Sep. 16, 2008.
International Search Report PCT-US-08-061447_ISR dated Sep. 16, 2008.
International Search Report PCT-US-12-030110_ISR dated Jul. 11, 2012.
International Search Report PCT-US-08-078976 WOSA dated Apr. 3, 2009.
International Search Report PCT-US-08-078976 IPRP dated Apr. 7, 2010.
International Search Report PCT-US-08-010520 IPRP dated Mar. 9, 2010.
International Search Report PCT-US-03-033373 ISR dated Mar. 15, 2004.
International Search Report PCT-US-08-010520 ISR dated Feb. 24, 2009.
International Search Report PCT-US-08-010520 WOSA dated Feb. 24, 2009.
Related Publications (1)
Number Date Country
20160199560 A1 Jul 2016 US